The Impact of Proton Pump Inhibitors on the Fecal Microbiome
Completed · Phase 1
Conditions studied: Healthy, Clostridium Difficile Infection
In brief
The investigators hypothesis is that daily use of a proton pump inhibitor (PPI) is associated with significant alterations in the healthy fecal microbiome that are similar to those seen in persons with an initial episode of clostridium difficile infection (CDI).
Key facts
- Study ID
- NCT01822977
- Run by
- Mayo Clinic
- People needed
- 15
- Starts
- 2013-03-01
- Expected to finish
- 2013-12-01
- Last updated by the study team
- 2014-08-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Mayo Clinic in Arizona — Scottsdale, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.